Patients with high-risk localized prostate cancer may benefit from intensifying neoadjuvant therapy—treatment administered before surgery—based on their specific genomic profile. Recent clinical investigations, including the GUNS trial, suggest that patients with aggressive genetic mutations see improved pathologic responses when treated with triplet regimens rather than standard androgen receptor pathway inhibitors.
Genomic Profiles and Treatment Intensification
For patients diagnosed with high-risk prostate cancer, the shift toward biomarker-directed therapy represents a move away from a “one-size-fits-all” approach.
CancerNetwork reported that while clinicopathologic risk stratification has long guided the use of androgen receptor pathway inhibitors (ARPI), current trials such as PROTEUS and the phase 3 DASL-HiCaP/ANZUP 1801 (NCT04136353) are testing whether intensifying to a triplet regimen—adding chemotherapy or other targeted agents—improves outcomes. The Genomic Umbrella Neoadjuvant Study (GUNS) provides evidence that not all high-risk prostate cancers respond equally to ARPI doublets.
Pathologic Response in Aggressive Genotypes
Subprotocol 2 of the GUNS trial specifically examined patients harboring aggressive genotypes, characterized by TP53 alterations, PTEN loss, AKT gain, or RB1 loss. These patients typically demonstrate poor or fleeting responses to standard ARPI doublet therapy.
When researchers intensified treatment to a triplet by adding docetaxel chemotherapy, they observed a change in residual cancer burden. This suggests that identifying these specific genomic markers could allow clinicians to tailor treatment intensity before surgical intervention.
Clinical Decision-Making for Radiotherapy
The choice between adjuvant radiotherapy—delivered immediately after surgery—and early salvage radiotherapy remains a critical decision point. According to a systematic review and meta-analysis published in The Lancet, both approaches yield similar long-term outcomes for most patients. However, adjuvant therapy exposes all patients to radiation, whereas early salvage targets only those who show evidence of recurrence.
Deferring radiation allows patients to recover from the physical toll of a prostatectomy, which is typically a 6-month process. By utilizing prostate-specific membrane antigen (PSMA) PET imaging, clinicians can now identify recurrence with higher precision. This allows for targeted salvage therapy only when the prostate-specific antigen (PSA) levels indicate a need, thereby sparing patients from unnecessary radiation and preserving sexual and bladder function.
| Trial/Study | Focus Area | Key Finding |
|---|---|---|
| GUNS (Subprotocol 1) | AR-driven biology | Intensification to triplet therapy increases depth of pathologic response. |
| GUNS (Subprotocol 2) | Aggressive genotype | Docetaxel triplets show 25% major pathologic response rate. |
| Vale et al. (Meta-analysis) | Radiotherapy timing | Early salvage yields outcomes comparable to adjuvant radiation. |
Evaluating Surgical Resectability
While clinical trials are expanding the options for systemic therapy, patients must be evaluated for surgical resectability before starting neoadjuvant treatment. Systemic therapy is not a tool to render unresectable disease resectable; it remains a strategy for high-volume, high-grade disease within the bounds of standard surgical judgment.
The Future of Neoadjuvant Studies
The next phase of prostate cancer research aims to move beyond hypothesis-generating trials like GUNS toward hypothesis-testing studies that measure clinically meaningful endpoints, such as metastasis-free survival. As genomic classifiers become more integrated into routine care, the ability to exploit the underlying biology of a tumor will likely define the next wave of perioperative management.
These efforts are supported by ongoing research into PARP inhibitors for BRCA-altered disease and AKT inhibitors for PTEN-altered disease, as noted by the clinical updates in the New England Journal of Medicine.